Medical News

RSS

APAF selects AB SCIEX TripleTOF 5600 System to help advance proteomics research

AB SCIEX, a global leader in life science analytical technologies, today announced that the Australian Proteome Analysis Facility has chosen the AB SCIEX TripleTOF 5600 System to help advance proteomics research by significantly expanding proteome coverage. The TripleTOF 5600 System is the life science industry's fastest and most sensitive high-resolution mass spectrometer for high-performance qualitative and quantitative analysis.

20 Sep 2010

Aradigm Corporation closes transaction with Novo Nordisk A/S

Aradigm Corporation today announced that it closed the transaction contemplated by the previously announced July 30, 2010 Stock Purchase Agreement with Novo Nordisk A/S. At the closing, the Company issued 26 million shares of the Company's common stock to Novo Nordisk A/S in a private placement as consideration for the termination of a promissory note in favor of Novo Nordisk A/S under which approximately $9.1 million was outstanding on July 30, 2010, representing an effective price per share of $0.3505.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

ICF International awarded re-compete contract to provide IT, scientific support services to NCTR

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a $31.8 million re-compete contract by the U.S. Food and Drug Administration to provide information technology and scientific support services to the National Center for Toxicological Research.

20 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

$Neovasc commences enrollment in Reducer trial for refractory angina$

Neovasc commences enrollment in Reducer trial for refractory angina

Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.

20 Sep 2010

LifePoint Hospitals intends to sell private offering of Senior Notes due 2020

LifePoint Hospitals, Inc. announced today its intention to sell through a private offering $400 million in aggregate principal amount of Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.

20 Sep 2010

Hatch Medical signs agreement with Majid Shano to broker super-elastic orthopedic stapling technology

Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has recently entered into an agreement with Majid Shano MB, B.CH., (Munich, Germany) to broker his patented, super-elastic orthopedic stapling technology.

20 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

First Edition: September 20, 2010

Today's headlines include news about the political positioning of both Democrats and Republicans on health reform, the mid-term elections and GOP plans to repeal and replace.

20 Sep 2010

3Pea International files registration statement on Form 10

3Pea International Inc., a payment solutions company, today announced that it has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) to register its common stock pursuant to Section 12(g) of the Securities Exchange Act of 1934.

20 Sep 2010

Actress Claire Danes joins thumbprint mosaic in Save the Children's EVERY ONE campaign

Emmy award winning actress Claire Danes will join millions of people who've added their thumbprints to an innovative and unique global petition at Grand Central Terminal, lead by global humanitarian organisation Save the Children.

20 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

Medical Accounts Systems, Jorge M. Abril, P.A. launch Healthcare Provider Payment

The staff at Medical Accounts Systems and the attorneys at Jorge M. Abril, P.A. are pleased to announce the launch of Healthcare Provider Payment, a blog dedicated to helping healthcare professionals and other interested parties stay abreast of relevant news and emerging trends in healthcare reimbursement, from insurance litigation news and Managed Care contracting issues, to health law and policy in general.

20 Sep 2010

Florida Hospital Fish Memorial acquires Toshiba's Xario XG ultrasound systems

Today's hospitals are under pressure to enhance patient care and streamline workflow while containing costs. To achieve this goal, Florida Hospital Fish Memorial acquired four XarioXG ultrasound systems from Toshiba America Medical Systems, Inc., to create imaging consistency across various departments.

20 Sep 2010

PAREXEL and Eli Lilly enter strategic functional service provider relationship

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the establishment of a strategic functional service provider relationship with Eli Lilly and Company, a global pharmaceutical company, to support study start-up and site monitoring of clinical trials throughout the Asia/Pacific region. PAREXEL will assist Lilly in bringing greater efficiencies to its clinical research studies to help meet Lilly's development and commercialization goals.

From Parexel 20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Myrexis releases MPC-9528 cancer metabolism inhibitor preclinical study results

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.

20 Sep 2010